Paradigm Biopharmaceuticals Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Phase 3
Recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: Pentosan Polysulfate Sodium twice weeklyDrug: Placebo
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Paradigm Biopharmaceuticals Ltd.
- Target Recruit Count
- 466
- Registration Number
- NCT06917404
- Locations
- 🇺🇸
Conquest Research, Winter Park, Florida, United States
🇺🇸Physician Research Collaboration, Lincoln, Nebraska, United States
🇦🇺Sportsmed Biologic LTD, Box Hill, Victoria, Australia
Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: Pentosan Polysulphate SodiumDrug: Placebo (Sodium Chloride Injection, 0.9%)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Paradigm Biopharmaceuticals Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT04814719
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇦🇺Emeritus Research, Camberwell, Victoria, Australia
News
No news found